Common new active substance approvals across major regulatory authorities (multi-year total) vs Antibody-drug conjugate trial starts
Common new active substance approvals across major regulatory authorities (multi-year total) (multi-month) and Antibody-drug conjugate trial starts (annual) worldwide. They are published at different intervals, so each is drawn on its own rather than matched period by period.
Change the pair
Compare different indicators
The series
Over time
Global. Common new active substance approvals across major regulatory authorities (multi-year total) is published as multi-month figures and antibody-drug conjugate trial starts as annual ones, so they are drawn on separate charts, and no period is matched between them. Read each on its own.
Common new active substance approvals across major regulatory authorities (multi-year total)
Unit: count · 2 observations
Antibody-drug conjugate trial starts
Unit: count · 6 observations
Shared periods
Side by side
No period lines up: common new active substance approvals across major regulatory authorities (multi-year total) is multi-month and antibody-drug conjugate trial starts is annual. A month and a year are not the same measurement window, so no row pairs them.
Provenance
Where these numbers come from
Common new active substance approvals across major regulatory authorities (multi-year total)
Total count of new active substances approved across all designated major regulatory authorities during the period.
2 observations charted in Global · source organisations: CIRS
Antibody-drug conjugate trial starts
Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in Global · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring